EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] loss -0.69% or -0.08 points to close at $11.46 with a heavy trading volume of 4400835 shares.
The daily chart for EYPT points out that the company has recorded -36.47% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 660.46K shares, EYPT reached to a volume of 4400835 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about EyePoint Pharmaceuticals Inc [EYPT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EYPT shares is $36.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EYPT stock is a recommendation set at 1.15. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Scotiabank have made an estimate for EyePoint Pharmaceuticals Inc shares, keeping their opinion on the stock as Sector Outperform, with their previous recommendation back on October 16, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on August 28, 2024, representing the official price target for EyePoint Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $35, while JP Morgan analysts kept a Overweight rating on EYPT stock.
The Average True Range (ATR) for EyePoint Pharmaceuticals Inc is set at 1.02, with the Price to Sales ratio for EYPT stock in the period of the last 12 months amounting to 12.17. The Price to Book ratio for the last quarter was 2.62, with the Price to Cash per share for the same quarter was set at 5.24.
Trading performance analysis for EYPT stock
EyePoint Pharmaceuticals Inc [EYPT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.06. With this latest performance, EYPT shares gained by 43.25% in over the last four-week period, additionally sinking by -36.47% over the last 6 months – not to mention a rise of 100.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EYPT stock in for the last two-week period is set at 62.60, with the RSI for the last a single of trading hit 63.24, and the three-weeks RSI is set at 61.13 for EyePoint Pharmaceuticals Inc [EYPT]. The present Moving Average for the last 50 days of trading for this stock 9.11, while it was recorded at 10.84 for the last single week of trading, and 14.77 for the last 200 days.
EyePoint Pharmaceuticals Inc [EYPT]: A deeper dive into fundamental analysis
EyePoint Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.69 and a Current Ratio set at 4.75.
An analysis of Institutional ownership at EyePoint Pharmaceuticals Inc [EYPT]
There are presently around $110.24%, or 111.86%% of EYPT stock, in the hands of institutional investors. The top three institutional holders of EYPT stocks are: CORMORANT ASSET MANAGEMENT, LP with ownership of 8.32 million shares, which is approximately 15.7334%. SUVRETTA CAPITAL MANAGEMENT, LLC, holding 5.18 million shares of the stock with an approximate value of $$45.03 million in EYPT stocks shares; and SUVRETTA CAPITAL MANAGEMENT, LLC, currently with $$32.75 million in EYPT stock with ownership which is approximately 7.1152%.
